• One of most common, severe diabetes complications; leading cause of blindness in working-age population *per planned protocol dosing Sources: Eye care of the patient with diabetes mellitus. American Optometric Association, Second Edition; Market Scope - 2022 Retinal Pharmaceuticals Market Report, Global Analysis 2021-2027; Market Scope Q2-2022 US Retina Quarterly Update; AAO DR Preferred Practice Pattern; JAMA Ophthalmol. 2021;139(9):946-955 (PANORAMA); Arcadu F, et al. NPJ Digit Med. 2019;2:92. • Diabeti ...

To date, we have reported interim data at two time points, seven months and 10 months, and have not observed any drug-related ocular or systemic series adverse events in OTX-TKI treated subjects. Importantly, the 73% of the OTX-TKI activated subjects who were rescue-free at month seven interim analysis remain rescue-free at month 10, highlighting what we believe is best-in-class durability. The ease of use of an office-based injection and long-term durability could establish OTX-TKI is the first standard of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (St ...

Thank you, Rabia. The company reported a net loss for the fourth quarter of 2022 of $15.5 million or a loss of $0.20 per share on a basic basis and a loss of $0.24 per share on a diluted basis compared to a net loss of $3.9 million or a net loss of $0.05 per share on a basic basis and a loss of $0.23 per share on a diluted basis for the same period in 2021. Net loss in the fourth quarter of 2022 included a $5.2 million noncash item attributable to a decrease in the fair value of the derivative liability ass ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President and Chief Executive Officer Rabia Ozden – Chief Medical Officer Peter Kaiser – Chief Medical Adviser-Retina Conference Call Participants Joe Catanzaro – Piper Sandler Kambiz Yazdi – Jefferies Yi Chen – H.C. Wainwright Yuan Zhi – B. Riley Georgi Yordanov – Cowen Caroline Palomeque – Berenberg Operator Good day, and thank ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President, CEO & Director Rabia Ozden - Chief Medical Officer Conference Call Participants Jonathan Wolleben - JMP Securities Stacy Ku - Cowen and Company Yi Chen - H.C. Wainwright & Co. Joseph Catanzaro - Piper Sandler & Co. Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix Second Quarter ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President & Chief Executive Officer Michael Goldstein – Chief Medical Officer Conference Call Participants Joe Catanzaro – Piper Sandler Dane Leone – Raymond James Jon Wollenben – JMP Securities Yi Chen – H.C. Wainwright Anita Dushyanth – Berenberg Capital Operator Good afternoon, ladies and gentlemen, thank you for standing by. And w ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Michael Goldstein - Chief Medical Officer Conference Call Participants Joe Catanzaro - Piper Sandler Jon Wolleben - JMP Securities Dane Leone - Raymond James Yi Chen - H.C. Wainwright Anita Dushyanth - Berenberg Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by a ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Antony Mattessich – CEO Donald Notman – CFO Dr. Michael Goldstein – Chief Medical Officer Scott Corning – Senior Vice President Commercial Chris White – Chief Business Officer Conference Call Participants Jon Wolleben – Participants Dane Leone – Raymond James Joe Catanzaro – Piper Sandler David Steinberg – Jefferies Anita Dushyanth – Berenberg Capital Georgi Yordanov – Cowen and Company Y ...